Pharmaceutical composition for piperidinoalkanol compounds
OwnerThomas T. Ortyl, Paul F. Skultety +6inventors
InventorsThomas T. Ortyl, Paul F. Skultety, Kristen C. Mitchell, Deepak S. Phadke, Faraneh Attarchi, Marquerite L. Pierce, Aaron W. Schoeneman, Joseph M. Schnitz
Life of this patent
Estimating the term…
Abstract
The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Claims43
A pharmaceutical composition comprising,
- a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof wherein said piperidinoalkanol compound has a particle surface area of greater than about 1.0 m2/g;
- and
- b) at least one inert ingredient.
A pharmaceutical composition in solid unit dosage form, comprising;
- a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof;
- and
- b) at least one inert ingredient.
A pharmaceutical composition prepared by a wet granulation process comprising, preparing the wet granulation wherein a compound of formula;
- 11
- wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, a diluent and a disintegrant are mixed with a solution of a binding agent;
- the wet granulation is screened, the wet granulation is dried, and the dry granulation is screened.
A pharmaceutical composition prepared by a wet granulation process comprising, preparing the wet granulation wherein a compound of formula;
- 12
- wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, a diluent and a disintegrant are mixed with a solution of a binding agent;
- the wet granulation is screened, the wet granulation is dried and the dry granulation is combined with a lubricant.
A pharmaceutical composition in solid unit dosage form prepared by a process comprising, blending together a compound of the formula;
- 13
- wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, lactose and pregelatinized starch;
- adding a solution of gelatin in water with mixing;
- drying and milling the mixture;
- and adding croscarmellose sodium with mixing.
A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula;
- 14
- wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, lactose and pregelatinized starch;
- adding a solution of gelatin in water with mixing;
- drying and milling the granulated mixture;
- adding croscarmellose sodium with mixing;
- and adding magnesium stearate with mixing.
A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula;
- 15
- wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, calcium carbonate and pregelatinized starch;
- adding a solution of gelatin in water with mixing;
- drying the granulated mixture;
- adding additional microcrystalline cellulose and sodium starch glycolate with blending;
- and adding magnesium stearate with blending.
A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula;
- 16
- wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, calcium carbonate and pregelatinized starch;
- adding water with mixing;
- drying the granulated mixture;
- adding additional microcrystalline cellulose and sodium starch glycolate, with blending;
- and adding magnesium stearate with blending.
Dependencies are inferred from the claim text.